From Disease Prevention to Trait Prediction
Traditionally, Preimplantation Genetic Testing (PGT) focused on "monogenic" diseases—disorders like cystic fibrosis caused by a single genetic glitch. However, Professor Tetsuya Ishii highlights a shift toward PGT-PS, which uses polygenic scores to estimate the likelihood of complex traits.

Unlike simple mutations, polygenic traits—such as intelligence, height, or the risk of Alzheimer’s and diabetes—are the result of a delicate dance between hundreds of genes and environmental factors.

"Predicting complex traits is still an exercise in high uncertainty," Ishii explains. "Polygenic scores look at DNA in a vacuum, ignoring the massive role that lifestyle and environment play in how a person actually develops."

A Global Regulatory Patchwork
The legal landscape for this technology is currently a "wild west" of varying standards:

United States: Commercially available since 2019; some clinics offer screening for both disease risks and non-medical traits.

Europe (Germany/Italy): Strictly limited to the prevention of severe hereditary illnesses.

United Kingdom: Currently prohibits the use of polygenic scoring for selecting embryos.

In many other regions, a lack of clear oversight means the technology could proliferate before scientists even agree on its clinical utility.

Ethical Red Flags and the "Designer" Dilemma
The ability to "rank" embryos based on genetic probability introduces profound societal risks:

The "Product" Mindset: Treating children as customized projects designed to meet parental expectations.

Stigmatization: Devaluing certain traits or conditions, potentially reviving eugenic ideologies.

False Promises: Parents may develop unrealistic expectations, forgetting that a child’s autonomy and environment will ultimately shape who they become.

Bridging the Expert-Public Gap
There is a growing disconnect between cautious medical professionals and a public that is increasingly open to "optimizing" their future children's genetics. Ishii argues that as the field accelerates, policymakers must step in with precautionary regulations.

The goal is not just to set limits, but to ensure the public understands the massive difference between a genetic "tendency" and a guaranteed outcome.